Lucid News· Jack Gorsline·AI score62
Policy briefing rounds up MDMA application resubmission, LSD phase 3 results and Canadian cannabis consortium
Psychedelic Policy Briefing 8.21.26
AI summary
A policy briefing reports that Resilient Pharmaceuticals, formerly Lykos Therapeutics and MAPS PBC.
Key facts
- Kind of item
- Trial results
- Compound
- LSD
- Condition
- Anxiety
- Jurisdiction
- United States
- Trial phase
- Phase 3
- Source
- Lucid News (lucid.news)
- Published
- Original
- Read it at lucid.news
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: Lucid News · lucid.news
Connected to
- Kind of item
- Trial results
- Compound
- LSD
- Condition
- Anxiety
- Jurisdiction
- United States